|
Clinical study supports the pharmacokinetic
and safety profile of RezularTM
Dublin, Ireland, 21 February
2008 - AGI Therapeutics plc ("AGI" or the
"Company") (AIM, IEX: AGI), a speciality pharmaceutical
company focused on gastrointestinal drug products,
today announces the key findings of a clinical study
to assess the pharmacokinetic profile of RezularTM
(AGI-003), which is in Phase III clinical trials
for the treatment of diarrhoea-predominant irritable
bowel syndrome (IBS-D). >
Learn More
AGI Therapeutics, plc Financial
results for the twelve months ended 31 December
2006
Dublin, Ireland, 11th April
2007 - AGI Therapeutics plc ("AGI" or the
"Company"), a speciality pharmaceutical company
focused on gastrointestinal drug products, today
reports audited financial results for the twelve
months ended 31 December 2006. >
Learn More
AGI Therapeutics plc FDA approval
to file IND for Arverapamil Phase III study
Dublin, Ireland, 11th April
2007 - AGI Therapeutics plc ("AGI"
or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal
drug products, today announces that it has concluded
a successful pre-IND (Investigational New Drug)
meeting with the U.S. Food and Drug Administration
(FDA) for arverapamil, (AGI-003), AGI's lead product
for irritable bowel syndrome (IBS). >
Learn More
AGI Therapeutics plc - Strengthens
management team
Dublin, Ireland, 12th March
2007 - AGI Therapeutics plc ("AGI" or the
"Company") (AIM, IEX: AGI), a speciality pharmaceutical
company focused on gastrointestinal drug products,
today announces the appointment of two new Vice
Presidents to its management team.
>
Learn More
AGI Therapeutics plc - Product
update and outlook for 2007
Dublin, Ireland, 15th February
2007 - AGI Therapeutics plc ("AGI"
or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal
drug products, today announces continued progress
on key development programmes and outlines its plans
for these programmes in 2007.
Following on from the reporting of clinical results
on 4 of its products in 2006 and the recent reporting,
earlier this month, of clinical results on its other
2 products, AGI is now in a position to map the
next key steps in progressing five of the original
six products in its pipeline into further clinical
development. >
Learn More
Preliminary clinical data for mecamylamine
(AGI-004) and arbaclofen (AGI-006)
Dublin, Ireland, 1st February
2007 - AGI Therapeutics plc ("AGI"
or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal
drug products, today announces preliminary results
of Phase II studies for mecamylamine (AGI-004, for
functional diarrhoea) and arbaclofen (AGI-006 for
functional dyspepsia). The results of these studies
follow the reporting last year of positive results
for other AGI products in development.
> Learn More
AGI Therapeutics plc appoints strong
Medical Advisory Panel.
Dublin, Ireland, 22nd January
2007 - AGI Therapeutics plc ("AGI"
or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal
drug products, today announces the appointment of
a Medical Advisory Panel of international experts
in the field of gastroenterology.
>
Learn More
AGI Therapeutics announces preliminary
results of phase II trial of espindolol (AGI-001)
in irritable bowel syndrome.
Dublin, Ireland, 29 September,
2006 - AGI Therapeutics plc (AIM, IEX: AGI,
"AGI" or the "Company"), a speciality
pharmaceutical company focused on gastrointestinal
(GI) drug products, today announces the preliminary
results of a phase II trial of the Company's espindolol
(AGI-001) product candidate for the treatment of
irritable bowel syndrome (IBS).
> Learn More
AGI Therapeutics plc signs $19
million exclusive license agreement with Axcan Pharma
for delayed/controlled release omeprazole.
Dublin, Ireland, 27th September
2006 - AGI Therapeutics plc ("AGI" or the
"Company") (AIM, IEX: AGI), a speciality pharmaceutical
company focused on gastrointestinal drug products,
today announces that it has entered into an exclusive
license agreement with Axcan Pharma, Inc. ("Axcan")
(NASDAQ: AXCA, TSX: AXP) for North American rights
to AGI's delayed/controlled release omeprazole formulation,
AGI-010. Axcan is a leading marketer of pharmaceutical
products for gastrointestinal diseases and disorders
in North America and Europe, with revenues in 2005
of over US $250 million.
>
Learn More
AGI Therapeutics, plc Interim financial
results for the six months ended 30 June, 2006.
Dublin, Ireland, 7th September
2006 - AGI Therapeutics plc ("AGI" or the
"Company"), a speciality pharmaceutical company
focused on gastrointestinal drug products, today
reports interim financial results for the six months
ended 30 June, 2006.
>
Learn More
AGI Therapeutics plc Appoints Chris
Blackwell as Non-Executive Director.
Dublin, Ireland, 13th July
2006 - AGI Therapeutics plc ("AGI" or the
"Company"), a speciality pharmaceutical company
focused on gastrointestinal drug products, today
announces the appointment of Dr. Chris Blackwell,
Chief Executive of Vectura Group plc, to its Board
of Directors.
>
Learn More
AGI Therapeutics Announces Preliminary
Results of Phase II Trials for Gastrointestinal
Disorders.
Dublin, Ireland, 7th June
2006 - AGI Therapeutics plc (AIM, IEX: AGI,
"AGI" or the "Company"), a speciality pharmaceutical
company focused on gastrointestinal (GI) drug products,
today announces the preliminary results of two Phase
II trials of its arverapamil (AGI-003) and espindolol
(AGI-001) product candidates.
>
Learn More
AGI Therapeutics plc appoints
Dr. David Young as President of US Operations.
Dublin, Ireland, 15th May
2006 - AGI Therapeutics plc (AIM, IEX: AGI),
a speciality pharmaceutical company focused on gastrointestinal
(GI) drug products, today announces the appointment
of David Young, Pharm.D. Ph.D., as President of
US Operations and Executive Member of the Board
of AGI. The appointment is effective from 5 June
2006. >
Learn More
AGI Therapeutics plc announces
appointment of Chief Financial Officer.
Dublin, Ireland, April 20th
2006 - AGI Therapeutics plc ("AGI" or the
"Company"), a speciality pharmaceutical company
focused on gastrointestinal drug products, today
announces the appointment of Mr. David G. Kelly
as director and Chief Financial Officer. Mr. Kelly's
appointment will be effective as of 2 May 2006.
>
Learn More
AGI Therapeutics plc Financial
results for the year ended 31 December 2005.
Dublin, Ireland, April 20th
2006 - AGI Therapeutics plc ("AGI" or the
"Company"), a speciality pharmaceutical company
focused on gastrointestinal drug products, today
reported the audited financial results for AGI Therapeutics
Research Limited, formerly AGI Therapeutics Ltd,
for the year ended 31 December 2005. AGI Therapeutics
Research Limited is the operating subsidiary of
AGI Therapeutics plc which was created as a holding
entity prior to the Company's recent flotation.
>
Learn More
AGI Therapeutics plc reports
results of clinical studies for two product candidates.
Dublin, Ireland, 29th March
2006 - AGI Therapeutics plc ("AGI"
or the "Company"), a speciality pharmaceutical
company focused on gastrointestinal drug products,
today reported the outcome of a clinical study on
its AGI-022 product candidate and preliminary data
from a clinical study on its AGI-010 product candidate.
Both product candidates are modified release oral
formulations of existing drugs used to treat gastrointestinal
diseases.
>
Learn More
AGI Therapeutics plc Admission
to trading on AIM and IEX €42.5 Million Placing.
Dublin, Ireland, 27 February
2006 - AGI Therapeutics plc ("AGI"
or the "Company"), a specialty pharmaceuticals
company focused on gastrointestinal drug products,
announces that admission to trading will become
effective, and dealings in its ordinary shares will
commence today on the AIM market of the London Stock
Exchange and the IEX market of the Irish Stock Exchange
(“Admission”).
>
Learn More
|
